 |
8 Diseases |  |
1 Trial |
|
1 Trial |  |
15 News |  |
- || AZD4017 / AstraZeneca
Trial completion: TICSI: Targeting Iatrogenic Cushing's Syndrome With 11?-hydroxysteroid Dehydrogenase Type 1 Inhibition (clinicaltrials.gov) - May 13, 2021
P2, N=32, Completed, Sponsor: University of Oxford
Recruiting --> Completed
- | AZD4017 / AstraZeneca
Trial completion date, Trial primary completion date: TICSI: Targeting Iatrogenic Cushing's Syndrome With 11?-hydroxysteroid Dehydrogenase Type 1 Inhibition (clinicaltrials.gov) - Mar 24, 2020
P2, N=32, Recruiting, Sponsor: University of Oxford
Recruiting --> Completed Trial completion date: Jan 2019 --> Aug 2020 | Trial primary completion date: Dec 2018 --> Aug 2020
- | AZD4017 / AstraZeneca
Trial completion: Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (clinicaltrials.gov) - Mar 22, 2019
P2, N=28, Completed, Sponsor: University of Leeds
Trial completion date: Jan 2019 --> Aug 2020 | Trial primary completion date: Dec 2018 --> Aug 2020 Recruiting --> Completed
- | AZD4017 / AstraZeneca
Trial completion date, Trial primary completion date: Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (clinicaltrials.gov) - Oct 12, 2018
P2, N=30, Recruiting, Sponsor: University of Leeds
Recruiting --> Completed Trial completion date: Sep 2018 --> Apr 2019 | Trial primary completion date: Sep 2018 --> Apr 2019
- | AZD4017 / AstraZeneca
New P2 trial: Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (clinicaltrials.gov) - Oct 18, 2017
P2, N=30, Not yet recruiting, Sponsor: University of Leeds
- | AZD4017 / AstraZeneca
Enrollment open: TICSI: Targeting Iatrogenic Cushing's Syndrome With 11?-hydroxysteroid Dehydrogenase Type 1 Inhibition (clinicaltrials.gov) - Oct 6, 2017
P2, N=32, Recruiting, Sponsor: University of Oxford
Trial completion date: Sep 2018 --> Apr 2019 | Trial primary completion date: Sep 2018 --> Apr 2019 Not yet recruiting --> Recruiting
- | AZD4017 / AstraZeneca
Trial completion: Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (clinicaltrials.gov) - May 8, 2017
P2, N=31, Completed, Sponsor: University of Birmingham
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | AZD4017 / AstraZeneca
New P2 trial: TICSI: Targeting Iatrogenic Cushing's Syndrome With 11?-hydroxysteroid Dehydrogenase Type 1 Inhibition (clinicaltrials.gov) - Apr 13, 2017
P2, N=32, Not yet recruiting, Sponsor: University of Oxford
- AZD4017 / AstraZeneca
Enrollment closed, Trial primary completion date: Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (clinicaltrials.gov) - Oct 26, 2016
P2, N=31, Active, not recruiting, Sponsor: University of Birmingham
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016
- | AZD4017 / AstraZeneca
Trial initiation date, Trial primary completion date: Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (clinicaltrials.gov) - Jun 26, 2015
P2, N=30, Recruiting, Sponsor: University of Birmingham
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016 Initiation date: Jan 2014 --> Apr 2014 | Trial primary completion date: Jan 2016 --> Aug 2016
- AZD4017 / AstraZeneca
Enrollment open: Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (clinicaltrials.gov) - Jun 27, 2014
P2, N=30, Recruiting, Sponsor: University of Birmingham
Initiation date: Jan 2014 --> Apr 2014 | Trial primary completion date: Jan 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- | AZD4017 / AstraZeneca
New P2 trial: Study of AZD4017 on markers of bone turnover in post-menopausal osteopaenia (EUDRACT) - Jan 28, 2014
P2, N=100, Ongoing, Sponsor: University of Birmingham
- AZD4017 / AstraZeneca
New P2 trial: Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (clinicaltrials.gov) - Dec 18, 2013
P2, N=30, Not yet recruiting, Sponsor: University of Birmingham
- | AZD4017 / AstraZeneca
Trial completion, P2 data, P2a data: A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure (clinicaltrials.gov) - Dec 18, 2012
P2a, N=50, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Completed